Want to see LFMD full AI Analyst Report?
LFMD Stock Chart & Stats
$3.25
$0.03(0.81%)
At close: 4:00 PM EDT
$3.25
$0.03(0.81%)
Day’s Range― - ―
52-Week Range$2.56 - $7.32
Previous CloseN/A
Volume267.82K
Average Volume (3M)914.66K
Market Cap
$147.01M
Enterprise Value$178.24
Total Cash (Recent Filing)$25.14M
Total Debt (Recent Filing)$6.02M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 11, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding48,200,836
10 Day Avg. Volume773,113
30 Day Avg. Volume914,661
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)6.65
Price to Sales (P/S)0.79
P/FCF Ratio-124.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.29Price Target Upside154.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$207.54M
Bulls Say, Bears Say
Bulls Say
Recurring Subscription RevenueAn 84% recurring revenue mix supports greater predictability than relying solely on one-time visits or transactions. Repeat subscriptions can improve retention economics, provide a durable customer base for cross-selling, and make future revenue planning more reliable as the platform expands.
High And Improving Gross MarginsGross margins near 89% indicate strong underlying economics in LifeMD’s digital care model. Further efficiency from provider utilization, fulfillment and pharmacy scale could preserve substantial contribution after direct costs, giving management room to fund growth and reduce operating losses.
Platform And Healthcare PartnershipsPartnerships with pharmaceutical and benefits platforms can broaden patient access beyond direct paid acquisition and strengthen LifeMD’s role in treatment delivery. The XYOSTED arrangement, insurer reach and major integrations create multiple channels that may support more diversified, durable growth.
Bears Say
Persistent Operating Losses And Cash BurnOngoing losses combined with negative operating and free cash flow show that the current business still consumes cash despite high gross margins. If profitability does not improve as guided, continued investment could reduce financial flexibility and increase reliance on external financing.
Revenue Contraction And Weaker Demand MomentumRevenue contraction after earlier expansion indicates that growth has not yet become durable across the portfolio. Lower sales can reduce operating leverage and make it harder to absorb fixed platform costs, while pricing and product-mix changes may continue to pressure near-term execution.
Customer Acquisition And Initiative Execution RiskDependence on paid media exposes LifeMD’s growth model to changing acquisition economics, while new programs require upfront spending before benefits arrive. This combination can delay sustained profitability and makes the success and timing of partnerships, pharmacy scale and product launches important.
LFMD FAQ
What was LifeMD’s price range in the past 12 months?
LifeMD lowest stock price was $2.56 and its highest was $7.32 in the past 12 months.
What is LifeMD’s market cap?
LifeMD’s market cap is $147.01M.
When is LifeMD’s upcoming earnings report date?
LifeMD’s upcoming earnings report date is Nov 11, 2026 which is in 57 days.
How were LifeMD’s earnings last quarter?
LifeMD released its earnings results on Aug 05, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.146 by -$0.014.
Is LifeMD overvalued?
According to Wall Street analysts LifeMD’s price is currently Undervalued.
Does LifeMD pay dividends?
LifeMD does not currently pay dividends.
What is LifeMD’s EPS estimate?
LifeMD’s EPS estimate is -0.14.
How many shares outstanding does LifeMD have?
LifeMD has 48,200,836 shares outstanding.
What happened to LifeMD’s price movement after its last earnings report?
LifeMD reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.146. Following the earnings report the stock price went down -7.609%.
Which hedge fund is a major shareholder of LifeMD?
Currently, no hedge funds are holding shares in LFMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.29 (154.95% Upside)
$8.29 (154.95% Upside)
Blogger Sentiment
Neutral
LFMD Sentiment 50%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 565.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
LifeMD
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.
LFMD Company Deck
LFMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strategic progress and near-term financial pressure. Positive operational signs include a high recurring revenue mix (84%), expanding gross margins (~89%), meaningful reductions in marketing and G&A, strong growth in women's health (134% QoQ), improving unit economics in RexMD, a scaling high-margin pharmacy (≈90% gross margin), expanding insurance reach (~175M covered lives), and partnerships such as XYOSTED and integrations with Lilly/NovoCare. Offsetting these positives were a Q2 adjusted EBITDA loss (~$3.5M), GAAP net loss ($7.9M), sequential revenue declines (~6%), pressured cash ($25.1M), elevated acquisition costs earlier in the quarter, and near-term investments and timing risks tied to new initiatives. Management expects a return to adjusted EBITDA profitability in Q3 and stronger results in Q4, but several initiatives require upfront investment and carry execution/timing risk.View all LFMD earnings summariesLFMD Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$8.29
▲(154.95% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
4.54% Insiders
10.23% Mutual Funds
7.50% Other Institutional Investors
68.56% Public Companies and
Individual Investors










